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Abstract
Background Palonosetron (Aloxi®, Onicit®) is a pharmaco-
logically unique 5-HT3 receptor antagonist (RA) approved
as a single IV injection for the prevention of nausea and
vomiting induced by chemotherapy (CINV) of either moderate
or highly emetogenic potential (MEC and HEC, respectively).
An oral palonosetron formulation has been developed and
compared to the IV formulation.
Methods In this multinational, multicenter, double-blind,
double-dummy, dose-ranging trial, 651 patients were
randomly assigned to receive one of the following as
a single dose prior to moderately emetogenic chemo-
therapy: oral palonosetron 0.25, 0.50, and 0.75 mg or
IV palonosetron 0.25 mg. Patients were also randomized
(1:1) to receive dexamethasone 8 mg IV or matched
placebo on day 1. The primary endpoint was complete
response (CR; no emesis, no rescue therapy) during the
acute phase (0–24 h).
Results Acute CR rates were 73.5, 76.3, 74.1, and
70.4 % for all patients receiving the palonosetron 0.25,
0.50, and 0.75 mg oral doses, and for IV palonosetron
0.25 mg, respectively; delayed CR (24–120 h) rates
were 59.4, 62.5, 60.1, and 65.4 %, and overall CR
(0–120 h) rates were 53.5, 58.8, 53.2, and 59.3 %,
respectively. The addition of dexamethasone improved
emetic control (acute CR rate) by at least 15 % for all
groups except oral palonosetron 0.25 mg, where the
acute CR improvement was approximately 7 %. Ad-
verse events were similar in nature, incidence, and in-
tensity for all oral and IV palonosetron groups, and
were the expected adverse events for 5-HT3 RAs (pri-
marily headache and constipation).
Conclusion Oral palonosetron has a similar efficacy and
safety profile as IV palonosetron 0.25 mg and may be
the preferred formulation in certain clinical situations.
Among the tested oral treatments, a palonosetron 0.50-
mg oral dose has been favored for the prevention of
CINV in patients receiving moderately emetogenic che-
motherapy due to a numerical gain in efficacy without a
side effect disadvantage.
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Introduction
Chemotherapy is frequently associated with nausea and
vomiting that can severely impair the ability of patients with
cancer to maintain daily functioning [1]. Since their intro-
duction into routine clinical practice, 5-HT3 receptor antag-
onists (RAs) have become the cornerstone of current
antiemetic prophylaxis and are an integral part of preventive
strategies for chemotherapy-induced nausea and vomiting
(CINV) [2]. The currently approved 5-HT3RAs include
ondansetron, granisetron, tropisetron, dolasetron, palonose-
tron, ramosetron, and azasetron.
Palonosetron is a pharmacologically unique 5-HT3RA
approved by the US Food and Drug Administration and
European Medicines Agency for the prevention of nausea
and vomiting associated with moderately and highly emeto-
genic chemotherapy (CINV) as a single intravenous dose
given before chemotherapy. Palonosetron can provide pro-
tection from emesis and nausea during both the acute and
the delayed phases of CINV [3–5]. It has a chemical struc-
ture that does not resemble the older 5-HT3RAs and exhib-
its distinct binding properties and a unique interaction with
the 5-HT3 receptor [6]. Although a similar pharmacokinetic
profile is achieved with similar oral and intravenous doses
of palonosetron in terms of area-under-the-curve drug expo-
sure (unpublished data), the possibility that the lower peak
concentration following oral administration might adversely
affect efficacy during the acute period suggested that higher
oral doses should be evaluated.
Dexamethasone is a standard component of antiemetic
combination regimens with first-generation 5HT3 RAs. The
present study investigated the efficacy and safety of a single
oral dose of palonosetron (0.25, 0.50, and 0.75 mg) com-
pared to a single IV dose of palonosetron (0.25 mg) in the
prevention of acute and delayed CINV in patients receiving
moderately emetogenic chemotherapy and also explored the
contribution of dexamethasone at these different dose levels.
Methods
Study characteristics
This was a randomized, multinational, multicenter, double-
blind, double-dummy, dose-ranging trial in which patients
were randomly assigned (stratified by gender and history of
chemotherapy [naïve vs non-naïve]) to one of four treat-
ments: oral palonosetron (0.25, 0.50, or 0.75 mg) or IV
palonosetron (0.25 mg). The study was approved by an
appropriate Institutional Review Board and Ethical Com-
mittee at each participating site. The study was conducted in
46 centers, 24 in Europe, 7 in Mexico, and 15 in the USA.
Patients in each treatment group were randomized (1:1 ratio)
to receive either a single dose of dexamethasone (8 mg IV)
or matched placebo on day 1 in addition to palonosetron.
Main inclusion and exclusion criteria
Eligible patients were male or female, 18 years of age
or older, with histologically or cytologically confirmed
malignant disease, Karnofsky index ≥50 %, either naïve
or non-naïve to cancer chemotherapy, and scheduled to
receive a single IV dose of at least one of the follow-
ing MEC agents administered on day 1: any dose of
oxaliplatin, carboplatin, epirubicin, idarubicin, doxoru-
bicin, ifosfamide, irinotecan, daunorubicin, or cyclo-
phosphamide <1,500 mg/m2 or cytarabine >1 g/m2.
Patients were excluded if treated with commercially
available IV palonosetron 0.25 mg within 2 weeks prior
to the start of study treatment or if scheduled to receive
any oral or intravenous dose of highly emetogenic
chemotherapy, radiotherapy of the upper abdomen or
cranium, or total body irradiation on days 1 to 5.
Patients were excluded if receiving any low-level
emetogenic chemotherapeutic agent (i.e., docetaxel,
paclitaxel, or pemetrexed) during days 1 to 5 if, in
the investigator's opinion, this necessitated co-administration
of antiemetics.
If a patient had known hepatic, renal, or cardiovas-
cular impairment or had a known history or predispo-
sition to cardiac conduction interval abnormalities,
including prolonged QTc, and was scheduled to receive
the above-mentioned chemotherapeutic agents, he/she
could be enrolled in the study at the discretion of the
investigator. Reliable contraceptive measures and a
negative pregnancy test at the pretreatment (screening)
visit were required for female patients of childbearing
potential.
Evaluation of efficacy and safety
The primary efficacy endpoint was complete response
(CR: no emesis, no rescue antiemetics) during the acute
phase (0–24 h after the start of the administration of the
first [most] emetogenic chemotherapeutic agent). The key
secondary endpoint was CR rates during the delayed
(24–120 h) phase. Additional secondary endpoints were
the overall CR rates (0–120 h) after administration of
chemotherapy, the proportion of patients with complete
control (defined as CR and no more than mild nausea),
without emetic episodes, without nausea, and without
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rescue medication, as well as the severity of nausea
(four-point Likert scale: none, mild, moderate, severe),
the time to first emetic episode, and patient global satis-
faction with antiemetic therapy. These parameters were
assessed and reported at various intervals during 0–
120 h, as acute, delayed, and overall phases. Safety
was assessed based on occurrence of adverse events, vital
signs, physical examination, 12-lead ECG, and laboratory
parameters. For all ECGs, PR, QRS, QT, QTcB, and
QTcF intervals, and heart rate were analyzed.
Statistical methods
The primary efficacy hypothesis was that at least one dose
of oral palonosetron was non-inferior to the approved IV
dose of palonosetron (0.25 mg) using a maximum delta of
15 %, considering the CR rate at 24 h. To demonstrate non-
inferiority, the lower bound of the two-sided 98.3 % confi-
dence interval of the difference between the 0–24 h CR rates
for each oral and IV dose of palonosetron were compared to
the preset threshold (−15 % difference). Results were eval-
uated on the full analysis set (FAS), defined as all random-
ized patients who received the study medication and at least
moderately emetogenic chemotherapy. The CR rates during
the other time periods (including the delayed and overall
phases) were examined using the same statistical methods as
for the primary efficacy endpoint (two-sided 98.3 % confi-
dence intervals).
The differences between the three oral doses of palono-
setron were tested using a two-sided non-inferiority test of
proportions with α=0.05 following the principle of closed
testing procedures. The proportion of patients who did not
experience emesis, the proportion of patients who did not
experience nausea, and the proportion of patients who did
not need rescue medication were analyzed using a chi-
square test. The severity of nausea was compared between
the treatment groups using Kruskal–Wallis and Mann–Whit-
ney tests. Time to first emetic episode was evaluated by
Kaplan–Meier estimates and log-rank test. All safety data
are presented using descriptive statistics.
Results
A total of 651 patients were enrolled; of these, 639 were
available for safety analyses since 12 patients who received
no study medication were excluded; four patients withdrew
from the study (Fig. 1). Thus, 635 patients were available
for efficacy analyses (FAS). Patient characteristics are sum-
marized in Table 1.
Fig. 1 CONSORT diagram
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Efficacy
Complete response
The CR (defined as no emesis and no rescue medication)
rates were generally similar in all treatment groups during
the acute (0–24 h) and delayed (24–120 h) phases, as well as
the overall 0–120 h time interval (Fig. 2). Non-inferiority
between the oral palonosetron 0.50 mg and IV 0.25 mg
groups was achieved in the acute and overall phases (acute:
lower bound of 98.3 % CI was −6.5 %; overall: lower bound
of 98.3 % CI was −14.2 %) but not in the delayed phase,
where a difference in CR rates of 2.9 % was seen (lower
bound of 98.3 % CI was −16.3 %; Table 2).
Similarly, in the acute phase (0–24 h), non-inferiority
was achieved for the 0.25 mg (lower bound of 98.3 %
CI was −8.9 %) oral doses and 0.75 mg (lower bound
of 98.3 % CI was −8.9 %) for oral doses compared to
the 0.25 mg IV formulation. In the delayed phase, none of the
oral doses tested reached non-inferiority to the IV dose
(0.25 mg oral: lower bound of 98.3 % CI was −19.7 %;
0.75 mg oral: lower bound of 98.3 % CI of −18.8 %). In the
overall phase, among the oral doses, only the 0.50 mg oral
dose was non-inferior to the 0.25 mg IV dose (0.25 mg oral:
lower bound of 98.3 % CI was −19.6 %; 0.75 mg oral: bound
of 98.3 % CI was −19.9 %).
Emetic episodes
The majority of patients in all treatment groups did not
suffer from emesis, and the proportion of patients with no
emetic episodes was similar across all treatment groups
during all time intervals (Fig. 3). No emesis rates ranged
from 77 to 83 % in the acute phase, 68–75 % in the delayed
phase, and 61–70 % in the overall phase. The highest rate of
protection from emesis among the oral doses was observed
in the oral palonosetron 0.50 mg group for the acute,
delayed, and overall periods. The highest difference in the
percentage of patients with no emetic episodes in favor of
oral palonosetron compared to IV palonosetron was seen
Table 1 Summary of patient characteristics (FAS)
Oral palonosetron IV palonosetron
0.25 mg (N=155) 0.50 mg (N=160) 0.75 mg (N=158) 0.25 mg (N=162)
Mean SD Mean SD Mean SD Mean SD
Age (years) 57.1 11.9 56.1 12.3 55.8 12.7 57.7 12.7
n % n % n % n %
Gender
Male 40 25.8 42 26.3 44 27.8 45 27.8
Female 115 74.2 118 73.8 114 72.2 117 72.2
Ethnic group
White 111 70.7 112 69.6 106 67.1 115 70.6
Black 2 1.3 1 0.6 2 1.3 0 0.0
Hispanic 43 27.4 45 28.0 49 31.0 45 27.6
Asian 1 .0.6 1 0.6 0 0.0 2 1.2
Other 0 0.0 2 1.2 1 0.6 1 0.6
Main cancer type
Breast cancer 81 52.3 82 51.3 82 51.9 85 52.5
Colon cancer 11 7.1 8 5.0 12 7.6 7 4.3
Lung malignant neoplasm 8 5.2 8 5.0 4 2.5 12 7.4
Chemotherapy history
Naïve 95 61.3 91 56.9 93 58.9 96 59.3
Non-naïve 60 38.7 69 43.1 65 41.1 66 40.7
Alcohol consumption
No 101 65.2 86 53.8 88 55.7 94 58.0
Rarely 30 19.4 41 25.6 43 27.2 34 21.0
Occasionally 21 13.5 27 16.9 25 15.8 31 19.1
Regularly 3 1.9 6 3.8 2 1.3 3 1.9
N number of patients in a specific group, n number of patients in the relevant category, % percentage based on N, SD standard deviation
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with the oral 0.50 mg dose during the acute phase. More
than 50 % of patients experienced no emetic episodes
throughout the 120-h time period.
Nausea
In the daily nausea assessment, the proportion of patients
with no nausea was comparable across all treatment groups,
with >78 % of patients having no more than mild nausea in
the oral palonosetron 0.50 mg (82.8 %) and IV palonosetron
0.25 mg groups (78.6 %) on each day. No statistically
significant difference was seen between oral palonosetron
0.50 mg vs IV palonosetron 0.25 mg for the proportion of
patients with no nausea during the acute, delayed, and
overall time intervals, as 58.8 vs 57.4 %, 49.4 vs 47.5 %,
and 45.6 vs 42.6 %, respectively (p=0.807; p=0.740, p=
0.583 in the acute, delayed, and overall phases).
Similarly, no statistically significant difference was
seen in the comparisons between 0.25 mg oral and
0.25 mg IV palonosetron in the acute, delayed, and
overall phases [respectively, 59.4 vs 57.4 % (p=0.725),
41.9 vs 47.5 % (p=0.316), 38.1 vs 42.6 % (p=0.411)]
and between 0.75 mg oral vs 0.25 mg IV palonosetron in
the acute [62.7 vs 57.4 % (p=0.337)], delayed [46.2 vs
47.5 % (p=0.811)], and overall phases [41.8 vs 42.6 %
(p=0.681)] (Fig. 4).
Efficacy in subgroups with and without dexamethasone
In the acute phase, all patient subgroups receiving dexa-
methasone showed higher CR rates than the corresponding
subgroups without dexamethasone (Table 2). In this phase,
the highest CR rate in patients who received dexamethasone
was seen in the oral 0.50 mg group (86.1 %). In the delayed
phase, CR was higher in the subgroups with dexamethasone
compared to the subgroups without dexamethasone, except
for the 0.25 mg oral group. In the delayed phase, the differ-
ences between the two subgroups with and without dexa-
methasone were less pronounced than in the acute phase. Of
note, the 0.25 mg oral group was the only group to show a
gain of <15 % in CR in the acute phase with the addition of
dexamethasone and was the only group to not show a gain
Table 2 Complete response rates in patients with or without concomitant dexamethasone (FAS)
Oral palonosetron IV palonosetron
0.25 mg (N=155) 0.50 mg (N=160) 0.75 mg (N=158) 0.25 mg (N=162)
% [95 % CI] % [95 % CI] % [95 % CI] % [95 % CI]
0–24 h Total 73.5 [65.8, 80.2] 76.3 [68.8, 82.5] 74.1 [66.4, 80.5] 70.4 [62.7, 77.1]
DEX Yesa 76.9 [65.8, 85.4] 86.1 [76.0, 92.5] 85.0 [74.9, 91.7] 82.9 [72.7, 90.0]
Nob 70.1 [58.5, 79.8] 66.7 [55.2, 76.5] 62.8 [51.1, 73.3] 57.5 [46.0, 68.3]
24–120 h Total 59.4 [46.7, 62.8] 62.5 [50.7, 66.4] 60.1 [46.3, 62.3] 65.4 [52.5, 68.0]
DEX Yesa 57.7 [46.0, 68.6] 63.3 [51.6, 73.6] 63.8 [52.2, 74.0] 68.3 [57.0, 77.9]
Nob 61.0 [49.2, 71.7] 61.7 [50.2, 72.1] 56.4 [44.7, 67.4] 62.5 [50.9, 72.9]
0–120 h Total 53.5 [45.4, 61.5] 58.8 [50.7, 66.4] 53.2 [45.1, 61.1] 59.3 [51.3, 66.8]
DEX Yesa 52.6 [41.0, 63.9] 63.3 [51.6, 73.6] 58.8 [47.2, 69.5] 65.9 [54.5, 75.7]
Nob 54.5 [42.8, 65.8] 54.3 [42.9, 65.3] 47.4 [36.1, 59.0] 52.5 [41.1, 63.7]
aN=319 with dexamethasone
bN=316 without dexamethasone
Fig. 2 Complete response rates
during the acute, delayed, and
overall phases of CINV (FAS,
N=635). Non-inferiority was
shown for oral palonosetron
0.50 mg vs IV palonosetron
0.25 mg for patients with no
emesis in the acute, delayed,
and overall phases
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in CR in the delayed phase or overall phase with the addi-
tion of dexamethasone (Table 2).
Due to the similar efficacy of the three oral doses tested,
the oral data were pooled and compared to IV palonosetron
with and without dexamethasone. In the acute period, in the
oral and IV groups, CR rates with dexamethasone were 82.7
and 82.9 %, respectively, compared to 66.5 and 57.5 %
without dexamethasone, respectively. In the delayed period,
in the oral and IV groups, CR rates were 61.6 and 68.3 %,
respectively, with dexamethasone, vs 58.7 and 62.5 %, re-
spectively, without dexamethasone. Finally, in the overall
period, CR rates were 58.2 and 65.9 % with dexamethasone
and 52.1 and 52.5 % without dexamethasone, respectively,
in the pooled oral and IV groups. Thus, a similar trend for
IVand oral palonosetron was seen, with a clinical advantage
when dexamethasone was added, mainly during the acute
phase.
Rescue medication
Consistent with the no emesis and no nausea results, the
percentage of patients using antiemetic rescue medication in
the 0.25, 0.50, and 0.75 mg oral groups was similar: 30.3 %
(n=47), 29.4 % (n=47), and 31.0 % (n=49), respectively,
compared to 29.0 % (n=47) in the IV palonosetron group.
Safety
The percentage of patients with treatment-emergent adverse
events was comparable in all four treatment groups (47–
50 %), with no dose response relationship noted for the oral
palonosetron groups. Treatment-related (possibly/probably
related) adverse events were reported with similar frequen-
cies in the three oral palonosetron groups (7.0, 8.1, and
7.6 % of patients for the 0.25, 0.50, and 0.75 mg doses,
respectively), while a higher percentage of patients with
related adverse events was seen in the IV palonosetron
group (16.0 % of patients). The most common treatment-
related adverse event in all treatment groups was headache,
which was comparable for its frequency in the three oral
palonosetron groups (0.25 mg, 3.8 %; 0.50 mg, 3.7 %;
0.75 mg, 3.8 %), but slightly higher in the IV palonosetron
group (8.6 %). Additionally, constipation was among the
most frequently reported treatment-related adverse event in
the oral 0.75 and 0.25 mg IV groups (3.2 and 3.1 %,
respectively) compared to the oral 0.25 and 0.50 mg groups
(0.6 % in each group).
Regardless of the relationship to the study drug, the
majority of the adverse events reported in this study did
not exceed mild intensity in all treatment groups. The type
and severity of adverse events were similar for the oral
Fig. 4 Proportion of patients
with no nausea in the different
treatment arms during the acute,
delayed, and overall phases
of CINV (FAS, N=635)
Fig. 3 Proportion of patients
with no emetic episodes in
the different treatment arms
during the acute, delayed,
and overall phases of
CINV (FAS, N=635)
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palonosetron and IV groups, and were typical for the 5-
HT3RA class.
Three adverse events led to withdrawal of two patients
from the study. One adverse event (thrombocytopenia, mild,
unrelated) occurred in the oral palonosetron 0.50 mg group;
two adverse events were serious and occurred in the 0.75 mg
treatment group (febrile neutropenia and septic shock, both
severe and fatal and unrelated to the study drug). There was
only one serious adverse event, assessed by the investigator
as being related to the study drug, in a patient who was
diagnosed with a chronic left bundle branch block at base-
line detected by ECG before any intake of study medication.
The same cardiac abnormality seen at baseline was seen 3 h
after administration of the study drug. The patient recovered
after hospitalization and pacemaker implantation.
No clinically relevant differences were observed between
the three oral palonosetron groups and the IV palonosetron
treatment group with regard to laboratory parameters, vital
signs, and 12-lead ECG. Possibly related ECG adverse events
were reported in ≤1.2 % of patients in all four treatments
groups. No pronounced differences were observed between
the four treatments concerning hematology or blood chemistry
parameters, or their changes during the study.
Discussion
Both oral and IV formulations of first-generation 5-HT3
RAs are effective, as reflected in current antiemetic guide-
lines [7–9]. Similarly, the three oral palonosetron doses
administered in this dose-ranging study (0.25, 0.50, and
0.75 mg) demonstrated consistent prevention of CINV
across several efficacy endpoints, as previously demonstrat-
ed for IV palonosetron 0.25 mg [3, 5, 6]. Efficacy results in
the 0–24-h period (acute phase) were not directly related to
the predicted plasma concentrations of palonosetron. In-
deed, all of the oral tested doses were non-inferior to the
0.25 mg IV formulation in the acute phase. Similar results
were also seen during the 0–120-h interval (overall phase).
During the delayed phase, CR rates were highest in the IV
palonosetron group followed by the 0.50, 0.75, and 0.25 mg
oral dose groups. Although statistical non-inferiority was
not achieved in the pre-specified analysis in the delayed
phase for any of the oral doses, the absolute difference in
CR rate between the oral 0.50 mg dose and the IV 0.25 mg
dose was only 2.9 %.
Although no clear dose response trends or significant
differences were seen between the oral doses, the 0.50 mg
oral dose demonstrated numerically higher antiemetic effi-
cacy rates compared to the other oral treatment arms in the
acute, delayed, and overall periods. Moreover, the 0.50 mg
dose was the only dose to show non-inferiority vs IV in the
overall CR. There were no significant differences between
any of the oral palonosetron treatment groups and the IV
group for the secondary endpoints of protection from eme-
sis, level of nausea, or use of rescue medication.
Administration of a single dose of dexamethasone with
palonosetron on day 1 led to substantially higher CR rates
during the acute phase in the oral 0.50 mg, oral 0.75 mg, and
IV 0.25 mg palonosetron groups. The additional efficacy
obtained with dexamethasone was less pronounced in the
delayed phase. Of note, the added benefit of dexamethasone
was lesser in magnitude in the oral 0.25 mg group, suggest-
ing that palonosetron 0.50 mg may be the lowest oral dose
for which full benefit is seen. Due to the similar efficacy of
the three oral doses tested, the data were pooled, and com-
parison of all the oral-treated patients with dexamethasone
confirmed the analysis of single oral doses vs the IV
formulation.
The safety profile of oral palonosetron was similar to that
of IV palonosetron in terms of overall frequency and inten-
sity of adverse events. However, headache was seen less
frequently with oral palonosetron, and constipation was
somewhat less frequent with the lower doses of oral palo-
nosetron. Analysis of adverse events, laboratory values,
vital signs, and 12-lead ECGs did not raise any safety
concerns for the administration of palonosetron as a single
oral dose. Concomitant dexamethasone did not introduce
substantial differences in the safety profiles compared to
the subgroups without dexamethasone.
Similar efficacy was found at all three oral doses com-
pared to IV administration of palonosetron. However, the
0.50 mg oral dose showed numerically superior efficacy
without a tolerability disadvantage. Considering the overall
efficacy and tolerability profile of oral palonosetron with or
without dexamethasone, oral palonosetron 0.50 mg can be
considered an acceptable therapeutic option for the preven-
tion of CINV from moderately emetogenic chemotherapy in
settings where an oral formulation is preferred.
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